Joshua Fitch is an editor for Contemporary Pediatrics.
Acknowledging obesity and hypertension in the pediatric population
A recap of the American College of Cardiology meeting and discussion of obesity and hypertension in the pediatric population.
Nirsevimab reduced RSV hospitalizations in infants by 82%, new data show
The new data, published in The Lancet, showed that nirsevimab substantially reduced RSV hospitalizations.
Parent perspectives: How are parents providing healthy diets for their children?
A recent nationally representative survey revealed what types of meals parents believe are healthy for their children, and how much food is the healthy amount.
Determining accuracy of ICD-10 influenza diagnosis codes in ED, inpatient settings
ICD-10 accuracy varied by age of the patient, influenza season definition, time between onset and testing, and clinical setting.
BLA resubmitted for lebrikizumab to treat AD patients 12 years and up
The resubmission was announced in a first quarter, 2024 earnings news release from Lilly, which expects "regulatory action in the second half of 2024."
Stigmatization of chronic skin disorders plays role in children's quality of life
Data from a recent study revealed that stigma associated with chronic skin diseases made an impact on the quality of life of affected children and adolescents.
A deep dive into Qbtech's diagnostic ADHD test
A discussion based on an FDA-cleared objective ADHD diagnostic test developed by Qbtech.
FDA approves mavorixafor as first drug for WHIM syndrome
The rare genetic disease causes the body's immune system to not function properly.
FDA accepts sNDA for tapinarof cream, 1% to treat AD in children 2 years and up
A decision from the federal agency is expected in the fourth quarter of 2024.
FDA approves diazepam for seizure clusters in patients 2 to 5 years
With the approval comes the immediate availability of 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses for patients between 2 to 5 years of age.
Week in review: FDA approvals, CRL for DEB, and more
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Marijuana legalization not associated with encouraged use among youth
Though concern exists about the associations of marijuana legalization and youth use, no links were found in a recent study.
Incorporating objective testing to add value to an ADHD diagnosis
Perry Roy, MD, explains how an FDA-cleared objective test can assist in an ADHD diagnosis.
FDA approves tovorafenib for most common form of childhood brain tumor
This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.
First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs
The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis
The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.
Week in review: BLA accepted for meningococcal vaccine, single-tablet HIV regimen data
Managing and treating eating disorders
A discussion of outpatient management and treatment of eating disorders in youth patients, plus the importance of a multidisciplinary team throughout the process.
FDA accepts BLA for meningococcal ABCWY vaccine, target action date set
The 5-in-1 vaccine candidate has the potential to reduce shots and simplify the immunization process.
Substance use trends among youth and importance of screenings
A discussion regarding current substance use trends for youth in the United States.
Reducing elevated non-HDL-C levels in childhood could prevent premature cardiovascular disease
“These findings suggest that primordial and primary interventions to prevent and reduce elevated childhood non–HDL-C levels may help prevent premature CVD," wrote the study authors.
Bictegravir, emtricitabine, and tenofovir alafenamide efficacy, safety in children with HIV 2 years and up
The low-dose, coformulated regimen was well tolerated, and overall data supports its use in children with HIV aged 2 years and older weighing between 30.86 lbs (14 kg) and 55.11 lbs (25 kg).
RSV monoclonal antibody nirsevimab to be 5% more expensive
The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.
Week in review: A new dermatology case study, and a new treatment for severe asthma
Patient-centered approach to updated AAP breastfeeding guidelines
Allison Scott, DNP, CPNP-PC, IBCLC, reviews the updated breastfeeding guidelines from the American Academy of Pediatrics.
Receptor targeting to identify medications for pediatric mental health concerns
Psychopharmacologic agents used in the pediatric population from the perspective of their interactions with receptor targets in the brain and body.
What the FDA approval of benralizumab means for children with severe asthma
Juanita Mora, MD, breaks down the FDA approval of benralizumab as an add-on maintenance therapy among patients with severe asthma aged 6 to 11 years.
Children younger than 5 years with HIV receiving ART have higher mortality than older persons
April 10, 2024 is National Youth HIV & AIDS Awareness Day.
Parents consider several factors when keeping a sick child home from school
When deciding whether to keep their child home from school, 4% of parents contacted a health care provider for advice.
Does vitamin C among pregnant smokers improve airway function trajectory in offspring?
"Our findings provide evidence for a direct association between maternal smoking during pregnancy and wheeze occurrence," wrote the authors.